Compare FLL & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLL | ONCY |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 94.0M |
| IPO Year | 1993 | 1999 |
| Metric | FLL | ONCY |
|---|---|---|
| Price | $2.56 | $0.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.00 | ★ $6.00 |
| AVG Volume (30 Days) | 196.9K | ★ 513.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $299,916,000.00 | N/A |
| Revenue This Year | $4.87 | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $2.25 | $0.33 |
| 52 Week High | $5.59 | $1.51 |
| Indicator | FLL | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 49.75 |
| Support Level | $2.51 | $0.86 |
| Resistance Level | $2.69 | $1.00 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 8.77 | 59.32 |
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.